Arstasis

The company's main product was the AXERA Access Device, also known as the Arstasis One Access System. This device was engineered to create a longer, shallower-angled entry into the femoral artery, called an "Arstaotomy." The benefit of this approach was that upon removal of the procedural sheath, the artery's natural blood pressure would cause the tissue layers to overlap and seal the opening, requiring only minimal manual compression. This method was designed to achieve rapid hemostasis without leaving a foreign body implant, thereby reducing risks of infection and thromboembolic events associated with traditional closure devices. For patients, this translated to quicker ambulation and shorter bed rest times.

Throughout its operation, Arstasis secured significant capital, raising a total of $102 million over four funding rounds. Notable funding events include a $25.5 million round in June 2011 and a subsequent round of $37.8 million in June 2012. The company received FDA 510(k) clearance for its Arstasis One system in May 2010. However, it also faced challenges, including a Class I FDA recall in February 2011 for its One Access system due to reports of device components potentially separating during procedures.